Reassuring Evidence: Anticancer Drug Does not Accelerate Tumor Growth after Treatment Ends (2 of 2) (image) Cell Press Share Print E-Mail Caption Studies in animals have raised concerns that tumors may grow faster after the anticancer drug sunitinib is discontinued. But oncologists and physicists who collaborated to analyze data from the largest study of patients with kidney cancer convincingly demonstrate that such tumor acceleration does not occur in humans. The findings, publishing online on Feb. 7th in the Cell Press journal Cell Reports, suggest that sunitinib does not cause lingering risks for patients after their treatment ends. Credit Cell Reports, Blagoev et al. Usage Restrictions Credit Required Share Print E-Mail Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.